April 09, 2026. 35 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis program aims to begin retail sales in spring 2026, affecting clinicians’ ability to recommend cannabis products to eligible patients in the state.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Cannabis cannabinoids CBD and CBG show potential therapeutic effects against hepatic steatosis, offering clinicians evidence-based rationale for investigating these compounds in fatty liver disease management protocols.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
This article examines regulatory enforcement actions against cannabis beverage companies, highlighting compliance challenges clinicians should understand when advising patients on product safety and legality.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A newly appointed cannabis regulator outlined priorities at their initial board meeting, establishing policy direction relevant to clinical practice and patient care standards.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s evolving cannabis regulations and their clinical implications for medical practitioners operating within the country’s changing legal framework.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Ohio breweries are legally challenging the state’s prohibition on THC-containing beverages, a regulatory issue affecting cannabis product availability and formulation standards in the beverage market.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio’s new law restricts THC-infused beverage distribution in retail settings, limiting patient access routes and requiring clinicians to understand evolving product availability for treatment recommendations.
Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, affecting dosing standardization and clinical product consistency for medical cannabis patients.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, relevant to clinicians seeking alternative administration techniques beyond smoking or standard ingestion.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
**Summary:** Study demonstrates CBD-dominant cannabis products effectively reduce anxiety symptoms, providing clinicians with evidence-based data for therapeutic recommendations and patient treatment planning.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing clinicians evidence-based data for treating this prevalent musculoskeletal condition.
Read more →As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
This article discusses a Supreme Court case relevant to medical cannabis patients and clinicians regarding legal protections or regulatory frameworks affecting medical cannabis practice and patient access.
Read more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
This article covers cannabis regulatory and legal developments from March 2026, providing clinicians with updates on compliance requirements and policy changes affecting clinical practice and patient care.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to inform patients about potential product safety issues and advise them to verify their cannabis product sources and batch numbers.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization is forming to prepare for upcoming Medicare pilot programs testing cannabidiol, which could expand clinical access and insurance coverage for CBD-based treatments.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This article covers legal prohibition status and regulatory frameworks for marijuana, which matters to cannabis clinicians because understanding jurisdictional legal restrictions directly affects treatment recommendations and patient counseling.
Read more →Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
A Louisiana legislator proposed legalizing recreational marijuana sales via regulated dispensaries, directly impacting clinical cannabis practice through potential changes to prescribing frameworks and patient access pathways.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has gained commercial distribution through state dispensaries, demonstrating patient-developed preparations entering regulated markets.
Read more →Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Virginia’s adult-use cannabis sales legislation passed both legislative chambers and requires conference committee reconciliation before potentially becoming law, affecting regulated market implementation and clinical practice standards.
Read more →Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
This article examines medical marijuana’s therapeutic benefits and drawbacks while Tennessee’s regulatory status remains uncertain, directly affecting clinical practice and patient access decisions.
Read more →2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
The 2026 Utah legislature will address cannabis, psychedelics, and kratom regulationโdirectly impacting clinicians’ ability to recommend these substances and patients’ legal access to treatment options.
Read more →Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
Georgia legislation may restrict police use of marijuana/cannabis/hemp odor as probable cause for searches, potentially affecting legal protections for patients and clinicians in the state.
Read more →Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
Market analysis projects prescription CBD oil revenues will reach $190.9 billion by 2032, reflecting significant growth that clinicians should monitor for treatment accessibility, product availability, and clinical evidence development.
Read more →InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
InMed Pharmaceuticals discontinued its non-therapeutic cannabis operations at BayMedica, redirecting resources toward clinical pharmaceutical developmentโrelevant to clinicians tracking cannabinoid-based therapeutic commercialization pathways.
Read more →Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
Pediatricians highlight cannabis use disorder in children and accessibility concerns, which matters to cannabis clinicians treating youth and developing age-appropriate clinical protocols.
Read more →West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
West Virginia legislators advanced a bill directing medical marijuana tax revenue allocation, establishing financial framework implementation relevant to clinical program operations and patient access infrastructure.
Read more →The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
This article examines roadside THC detection methods and Saskatchewan Government Insurance’s zero-tolerance impaired driving policy, relevant to clinicians assessing patient safety and legal implications of cannabis use.
Read more →‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
Tennessee’s proposed “Pot for Potholes Act” would legalize marijuana and dedicate tax revenue to infrastructure, requiring clinicians to understand potential changes to prescribing regulations and patient access.
Read more →One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword
One of Colorado’s largest cannabis dispensary chains is being acquired, which may affect patient access, pricing, and product availability in the state’s regulated market.
Read more →Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN
**Legalization correlates with increased marijuana consumption among US adults from historically underrepresented populations, requiring clinicians to understand evolving epidemiology and access patterns.**
Read more →What’s Really Happening With Cannabis ETF MSOS? – The Dales Report
To help you, please share the article text or key details about what MSOS performance trends, regulatory changes, or market factors it discusses.
Read more →Scientists are raising new concerns about marijuana use in teens – KPBS
Adolescent cannabis use is associated with elevated psychiatric risks including psychosis, depression, and anxiety, making age-specific patient assessment and counseling essential for clinical practice.
Read more →Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
Prenatal cannabis exposure may affect fetal neurodevelopment through placental disruption, with placental biomarkers potentially identifying early schizophrenia risk in exposed pregnancies.
Read more →Digest-Level Clinical Commentary
These items signal that cannabis medicine is simultaneously maturing through clinical evidence and formulation innovation while facing significant regulatory fragmentation that could undermine patient access and safety. The emergence of rigorous research on cannabinoid delivery systems and condition-specific efficacy, coupled with new scientific advisory bodies, contrasts sharply with the patchwork of state-level restrictions on dosing, product types, and THC content that practitioners must navigate. As a clinician, I’m watching whether we can establish evidence-based prescribing standards before regulatory inconsistency forces patients toward uncontrolled alternatives or creates disparities in treatment availability across state lines.
These items reflect a maturing cannabis market characterized by expanding medical access, growing clinical evidence supporting specific cannabinoid applications, and ongoing regulatory fragmentation across jurisdictions. The clinical evidence highlighted suggests CBD and cannabinoid extracts may have legitimate therapeutic roles in conditions like anxiety and myofascial pain, though formulation delivery methods and product standardization remain significant challenges. Concurrently, regulatory inconsistency around THC beverages and edible potency caps demonstrates that policy development has not kept pace with product innovation or the emerging clinical literature.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: